Regulation of IL-13 transcription in human T-cells by GATA-3/NF-AT complexes: modulation by corticosteroids

GATA-3/NF-AT 复合物对人 T 细胞中 IL-13 转录的调节：皮质类固醇的调节

• 批准号: G0801266/1
• 负责人: Ian Adcock
• 金额: $ 45.59万
• 依托单位: Imperial College London
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2009
• 资助国家: 英国
• 起止时间: 2009 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=G0801266%2F1
• 关键词: Regulation; IL; 13; transcription; human

Asthma affects 1 in 12 of the UK population, with 5.2 million people currently receiving treatment. The UK has one of the highest prevalence of asthma in young adults in Europe and the numbers of children reporting asthma symptoms has risen six fold over the last 30 years. Asthma costs the NHS #889m per year and it is estimated that at least 12.7 million working days are lost due to asthma each year. The rising prevalence of allergic diseases and accompanying health care costs are therefore major health and socio-economic problems. Most asthmatic subjects respond to treatment with inhaled corticosteroids although the mechanisms underlying their action are not clear. We wish to determine how corticosteroids reduce the expression of key proteins involved in asthma particularly the inflammatory mediator interleukin 13 (IL-13). Understanding how corticosteroids work in mild asthma may help to develop new drugs to target these processes that have fewer side-effects and may be able to treat patients with severe asthma who do not improve with corticosteroids. This will result in improved patient care with less side-effects and in cost savings to the NHS,

英国每12人中就有1人患有哮喘，目前有520万人正在接受治疗。英国是欧洲年轻人中哮喘患病率最高的国家之一，报告哮喘症状的儿童数量在过去30年里增加了6倍。哮喘每年花费国民健康保险制度8.89亿英镑，据估计，每年至少有1270万个工作日因哮喘而损失。因此，过敏性疾病患病率的上升和随之而来的保健费用是主要的健康和社会经济问题。大多数哮喘患者对吸入皮质类固醇治疗有反应，尽管其作用机制尚不清楚。我们希望确定皮质类固醇如何减少哮喘相关关键蛋白的表达，特别是炎症介质白介素13(IL-13)。了解皮质类固醇如何在轻度哮喘中发挥作用，可能有助于开发针对这些过程的新药，这些药物副作用较少，可能能够治疗未经皮质类固醇改善的重度哮喘患者。这将以更少的副作用改善患者护理，并为NHS节省成本，